Actively Recruiting

Phase 2
Age: 6Years - 11Years
All Genders
NCT06553547

4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs

Led by Ardelyx · Updated on 2026-05-12

72

Participants Needed

20

Research Sites

96 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a randomized, double-blind, placebo-controlled dose-ranging study to assess the safety and efficacy of tenapanor for treatment of the IBS-C in pediatric patients 6 to less than 12 year old.

CONDITIONS

Official Title

4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs

Who Can Participate

Age: 6Years - 11Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  1. ≥6 and <12 years old at the Screening visit (Visit 1)
  2. Confirmation of negative pregnancy test and use of appropriate contraceptive (including abstinence) in female subjects that have experienced menarche and are of child-bearing potential.
  3. Meet the Modified Diagnostic Rome IV criteria for child/adolescent diagnosis of IBS-C
  4. Patient is willing to discontinue any laxatives used in favor of the protocol-permitted rescue medicine (which will only be allowed after 72 hours with no bowel movement)
  5. Meet the entry criteria assessed during the 2-week Screening period
  6. Ability of both the patient and parent/guardian/LAR to communicate with the Investigator and to comply with the requirements of the entire study, including an understanding of the assessments in the eDiary and how to use the eDiary device
  7. Patient must provide verbal assent and the parent/guardian/LAR must provide written informed consent before the initiation of any study-specific procedures
Not Eligible

You will not qualify if you...

  1. Functional diarrhea as defined by Modified Rome IV child/adolescent criteria

  2. IBS with diarrhea (IBS-D), mixed IBS (IBS-M), or unsubtyped IBS as defined by Modified Rome IV child/adolescent criteria

  3. History of non-retentive fecal incontinence;

  4. Required manual disimpaction any time prior to randomization (after consent)

  5. Currently has both unexplained and clinically significant alarm symptoms (lower gastrointestinal [GI] bleeding [rectal bleeding or heme-positive stool], iron-deficiency anemia, or any unexplained anemia, or weight loss) and systemic signs of infection or colitis, or any neoplastic process.

  6. Patient has any of the following conditions:

    1. Celiac disease, or positive serological test for celiac disease and the condition has not been ruled out by endoscopic biopsy;
    2. Cystic fibrosis;
    3. Hypothyroidism that is untreated or treated with thyroid hormone at a dose that has not been stable for at least 3 months prior to the Screening Visit;
    4. Down's syndrome or any other chromosomal disorder;
    5. Active anal fissure (Note: History of anal fissure is not an exclusion);
    6. Anatomic malformations (eg, imperforate anus, anal stenosis, anterior displaced anus);
    7. Intestinal nerve or muscle disorders (eg, Hirschprung disease, visceral myopathies, visceral neuropathies);
    8. Neuropathic conditions (eg, spinal cord abnormalities, neurofibromatosis, tethered cord, spinal cord trauma);
    9. Lead toxicity, hypercalcemia;
    10. Neurodevelopmental disabilities
    11. Inflammatory bowel disease
    12. Childhood functional abdominal pain syndrome
    13. Childhood functional abdominal pain
    14. Poorly treated or poorly controlled psychiatric disorders that might influence his or her ability to participate in the study;
    15. Lactose intolerance that is associated with abdominal pain or discomfort and could confound the assessments in this study
    16. History of cancer other than treated basal cell carcinoma of the skin;
    17. History of diabetic neuropathy.
  7. Use of medications that are known to affect stool consistency (Prohibited Medications), including fiber supplements, anti-diarrheals, cathartics, antacids, opiates, prokinetic drugs, laxatives, enemas, antibiotics during the Screening period; unless specified as rescue medication, and used accordingly as directed by the Investigator.

  8. Patient has had surgery that meets any of the following criteria:

    1. Surgery to remove a segment of the GI tract at any time before the Screening Visit;
    2. Surgery of the abdomen, pelvis, or retroperitoneal structures during the 6 months before the Screening Visit;
    3. An appendectomy or cholecystectomy during the 60 days before the Screening Visit;
    4. Other major surgery during the 30 days before the Screening Visit
  9. History of alcohol or substance abuse

  10. Participation in other clinical trials within 1 month prior to Screening

  11. Patient and/or parent/guardian/LAR is involved in the conduct and/or administration of this trial as an investigator, sub-investigator, trial coordinator, or other staff member, or the patient is a first-degree family member, significant other, or relative residing with one of the above persons involved in the trial

  12. If, in the opinion of the Investigator, the patient is unable or unwilling to fulfill the requirements of the protocol or has a condition, which would render the results uninterpretable

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 20 locations

1

Applied Research Center of Arkansas

Little Rock, Arkansas, United States, 72205

Actively Recruiting

2

Connecticut Children's Medical Center

Hartford, Connecticut, United States, 06106

Actively Recruiting

3

Waterway Research & Associates Corp.

Miami, Florida, United States, 33155

Actively Recruiting

4

Valencia Medical and Research Center

Miami, Florida, United States, 33165

Actively Recruiting

5

Orlando Health, Inc.- APH Center for Digestive Health and Nutrition

Orlando, Florida, United States, 32806

Actively Recruiting

6

Florida Pharmaceutical Research and Associates, Inc.

South Miami, Florida, United States, 33143

Actively Recruiting

7

OSF Saint Francis Medical Center

Peoria, Illinois, United States, 61637

Actively Recruiting

8

Mankato Clinic Children's Health Center

Mankato, Minnesota, United States, 56001

Actively Recruiting

9

Boys Town National Research Hospital

Boys Town, Nebraska, United States, 68010

Actively Recruiting

10

SUNY Downstate Medical Center

Brooklyn, New York, United States, 11203

Actively Recruiting

11

Wilmington Health

Wilmington, North Carolina, United States, 28401

Actively Recruiting

12

Akron Children's Hospital

Akron, Ohio, United States, 44308

Actively Recruiting

13

Prisma Health Children's Hospital

Greenville, South Carolina, United States, 29615

Actively Recruiting

14

Maspons Pediatric Gastro

El Paso, Texas, United States, 79902

Actively Recruiting

15

Proactive El Paso, LLC

El Paso, Texas, United States, 79902

Actively Recruiting

16

Texas Digestive Specialists

Harlingen, Texas, United States, 78550

Actively Recruiting

17

Sun Research Institute

San Antonio, Texas, United States, 78215

Actively Recruiting

18

Pioneer Research Solutions Inc

Sugar Land, Texas, United States, 77479

Actively Recruiting

19

Clinical Research Partners, LLC

Richmond, Virginia, United States, 23226

Actively Recruiting

20

University Physicians and Surgeons, Inc

Huntington, West Virginia, United States, 25701

Actively Recruiting

Loading map...

Research Team

S

Shannon Song

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

7

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here